EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	124	chlorophorm	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/07/08 19:00
L2	221804	chloroform	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/07/08 19:00
L3	5319	l2 same carrier	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/07/08 19:00
L4	1378	l2 same carrier same pharma$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/07/08 19:00
L5	66	l2 near10 carrier same pharma$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/07/08 19:11
L6	5	"6638928"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/07/08 19:11

10728179

INVENTOR SEARCH

=> d ibib abs hitstr 16 1-3

L6 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1080692 HCAPLUS Full-text
DOCUMENT NUMBER: 142:56375
TITLE: Modulation of dopamine responses with substituted (S)-2,3-benzodiazepines
INVENTOR(S): Leventer, Steven M.; Harris, Herbert W.; Kucharik, Robert F.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004254173	A1	20041216	US 2003-461290	20030613
PRIORITY APPLN. INFO.:			US 2003-461290	20030613

OTHER SOURCE(S): MARPAT 142:56375
GI



I

AB There is provided a method of modulating dopamine responses in the central nervous system of an individual or a method of treating a dopamine-mediated disorder in an individual not suffering from seizures or convulsions which comprises administering to the individual an effective amount of at least one compound of formula (I) [R1 = C1-7 hydrocarbyl or C2-6 heteroalkyl; R2 = H, C1-7 hydrocarbyl; wherein R1 and R2 may combine to form a carbocyclic or heterocyclic 5- or 6-membered ring; R3, R4, R5, R6 = OH, C1-7 hydrocarbyl, CF3, C1-7 hydrocarbyloxy, acyloxy, NH2, -NH(C1-6alkyl), -N(C1-6 alkyl)2, -NH-acyl, halogen; wherein R5 and R6 may combine to form a 5-, 6- or 7-membered heterocyclic ring] or pharmaceutically acceptable salts thereof or said compound comprising an (S)-enantiomer substantially free of the (R)-enantiomer of the same compound The above dopamine-mediated disorder comprises a neurol. disorder or a neuropsychiatric disorder. The neurol. disorder includes Huntington's chorea, Parkinson's disease, periodic limb movement syndrome, restless leg syndrome, hyperkinesias, Tourette's syndrome, Pick's disease, punch drunk syndrome, progressive subnuclear palsy, multiple systems atrophy, Landau-Kleffner syndrome, benign essential blepharospasm, amyotrophic lateral

sclerosis, medication-induced movement disorders, and cognitive disorders. The neuropsychiatric disorder includes psychosis, personality disorders, psychiatric mood disorders, conduct and impulse disorders, schizophrenia, bipolar disorders, dysphoric mania, anxiety disorders, depression, panic disorders, agoraphobia, obsessive-compulsive disorders and eating disorders. Thus, 4.41 g (10 mmol) 1-(3,4-dimethoxyphenyl)-3- methyl-4-ethyl-6,7-dimethoxyisobenzopyrilium chloride hydrochloride was dissolved in methanol (35 mL) at a temperature of 40°. After cooling to 20-25°, hydrazine hydrate (0.75 g, 15 mmol, dissolved in 5 mL methanol) was added and the resulting mixture was allowed to react while monitoring the reaction by HPLC and when complete, was evaporated to dryness. The residue was triturated with cold water (3 mL), filtered and dried to yield the crude 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-hydroxy-8- methoxy-5H-2,3-benzodiazepine (racemic tofisopam) which was subsequently triturated with hot EtOAc to yield the pure product. Racemic tofisopam was resolved by a Chirobiotic V column (ASTEAC, Whippany, N.J.) to give (R)-tofisopam and (S)-tofisopam. (R)-tofisopam did not affect apomorphine-induced hypothermia in mice. Racemic tofisopam at 64 mg/kg tended to behave as a weak dopamine antagonist, i.e., lowering the rectal temperature at the thirty and sixty minute time points. However this trend was not statistically significant. (S)-tofisopam behaved as a weak dopamine antagonist at the 16 mg/kg dose at sixty minutes after apomorphine administration, i.e., showing a slight but statistically significant elevation in temperature At the higher doses, (S)-tofisopam demonstrated dopamine antagonism at both the thirty minute and sixty minute time points, i.e., lowering the rectal temperature at both time points.

IT 75114-20-4P, 1-(3-Hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (S)-2,3-benzodiazepines for modulation of dopamine responses
and treatment of neurol. disorders or neuropsychiatric disorders)

RN 75114-20-4 HCAPLUS

CN Phenol, 5-(5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepin-1-yl)-2-methoxy- (CA INDEX NAME)



IT 730962-81-9P, (S)-1-(3-Hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (S)-2,3-benzodiazepines for modulation of dopamine responses
and treatment of neurol. disorders or neuropsychiatric disorders)

RN 730962-81-9 HCAPLUS
CN Phenol, 5-[(5S)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepin-1-yl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:633284 HCAPLUS Full-text
DOCUMENT NUMBER: 141:162379
TITLE: Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof
INVENTOR(S): Harris, Herbert W.; Leventer, Steven M.; Kucharik, Robert F.
PATENT ASSIGNEE(S): Vela Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004152695	A1	20040805	US 2003-728179	20031203
CA 2510275	A1	20040819	CA 2003-2510275	20031203
WO 2004069155	A2	20040819	WO 2003-US38641	20031203
WO 2004069155	A3	20060112		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003303312	A1	20040830	AU 2003-303312	20031203
EP 1575521	A2	20050921	EP 2003-815301	20031203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514084	T	20060427	JP 2004-568017	20031203

PRIORITY APPLN. INFO.:
US 2002-430770P P 20021203
WO 2003-US38641 W 20031203

AB Pharmaceutical compns. comprise 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or a pharmaceutically acceptable salt thereof. The compns. are used for treating, preventing or delaying the onset of disorders mediated by LTB4 or TXA2.

IT 57576-52-0, Thromboxane a2
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(composition containing 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine for treatment of disorders mediated by LTB3 and TXA2)

RN 57576-52-0 HCAPLUS

CN 5-Heptenoic acid, 7-[(1S,3R,4S,5S)-3-[(1E,3S)-3-hydroxy-1-octen-1-yl]-2,6-dioxabicyclo[3.1.1]hept-4-yl]-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 71160-24-2, Ltb4
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(composition containing 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine for treatment of disorders mediated by LTB3 and TXA2)

RN 71160-24-2 HCAPLUS

CN 6,8,10,14-Eicosatetraenoic acid, 5,12-dihydroxy-, (5S,6Z,8E,10E,12R,14Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 75114-20-4, 1-(3-Hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine 697754-51-1 730962-81-9
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(composition containing 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine for treatment of disorders mediated by LTB3 and TXA2)

RN 75114-20-4 HCAPLUS

CN Phenol, 5-(5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepin-1-yl)-2-methoxy- (CA INDEX NAME)



RN 697754-51-1 HCAPLUS
CN Phenol, 5-[(5R)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepin-1-yl]-2-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 730962-81-9 HCAPLUS
CN Phenol, 5-[(5S)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepin-1-yl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:490707 HCAPLUS Full-text
DOCUMENT NUMBER: 141:33842
TITLE: Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof

INVENTOR(S): Kucharik, Robert F.; Leventer, Steven M.; Harris, Herbrt W.
PATENT ASSIGNEE(S): Vela Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050040	A2	20040617	WO 2003-US38642	20031203
WO 2004050040	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508542	A1	20040617	CA 2003-2508542	20031203
AU 2003293405	A1	20040623	AU 2003-293405	20031203
US 2004157833	A1	20040812	US 2003-728261	20031203
EP 1567161	A2	20050831	EP 2003-790352	20031203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006510634	T	20060330	JP 2004-557606	20031203

PRIORITY APPLN. INFO.:
US 2002-430771P P 20021203
WO 2003-US38642 W 20031203

AB Pharmaceutical compns. comprising 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl- 7-methoxy-8-hydroxy-5H-2,3-benzodiazepine (I) or a pharmaceutically acceptable salt thereof are described. The compns. are used for treating, preventing or delaying the onset of disorders mediated by LTB4, TXA2 or adenosine. For example, I demonstrated statistically significant anticonvulsant activity at 30 and 45 mg/kg doses. The 60 mg dose showed comparable anticonvulsant activity, but fell short of statistical significance. This is likely a consequence of the small number of tested animals,.

IT 57576-52-0, Thromboxane A2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(disorders mediated by; preparation of benzodiazepine derivative for treatment
of disorders mediated by adenosine, LTB4 or TXA2)

RN 57576-52-0 HCAPLUS
CN 5-Heptenoic acid, 7-[(1S,3R,4S,5S)-3-[(1E,3S)-3-hydroxy-1-octen-1-yl]-2,6-dioxabicyclo[3.1.1]hept-4-yl]-, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 71160-24-2, LTB4
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inflammation mediated by; preparation of benzodiazepine derivative for treatment of disorders mediated by adenosine, LTB4 or TXA2)
RN 71160-24-2 HCAPLUS
CN 6,8,10,14-Eicosatetraenoic acid, 5,12-dihydroxy-, (5S,6Z,8E,10E,12R,14Z)-
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



SEARCH OF REGISTRY, CAPLUS, AND USPATFULL

```
=> d que stat l20
L8             1 SEA FILE=REGISTRY ABB=ON  697754-51-1/RN
L9             7 SEA FILE=HCAPLUS ABB=ON  L8
L10            7 SEA FILE=USPATFULL ABB=ON  L8
L11            7 DUP REMOV L9 L10 (7 DUPLICATES REMOVED)
L13              STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  27

STEREO ATTRIBUTES: NONE
L15           78 SEA FILE=REGISTRY SSS FUL L13
L16          222 SEA FILE=HCAPLUS ABB=ON  L15
L18           20 SEA FILE=USPATFULL ABB=ON  L16 AND R(W)ENANTIOMER?
L19           20 DUP REMOV L11 L18 (7 DUPLICATES REMOVED)
L20            3 SEA L19 AND (PRD<20021203 OR PD<20021203)


=> d ibib abs hitstr l20 1-3

L20  ANSWER 1 OF 3  USPATFULL on STN
ACCESSION NUMBER:        2006:196220  USPATFULL  Full-text
TITLE:                   Compositions and methods for treating or preventing
                         convulsions or seizures
INVENTOR(S):             Leventer, Steven M., Langhorne, PA, UNITED STATES
                         Kucharik, Robert F., Glenmoore, PA, UNITED STATES
PATENT ASSIGNEE(S):      Vela Pharmaceuticals, Inc., Ewing, NJ, UNITED STATES
                         (U.S. corporation)

                              NUMBER         KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2006166976      A1   20060727
APPLICATION INFO.:       US 2006-388399     A1   20060324  (11)
RELATED APPLN. INFO.:    Continuation of Ser. No. US 2003-625754, filed on 23
                         Jul 2003, PENDING Continuation of Ser. No. US
```

2001-8516, filed on 8 Nov 2001, GRANTED, Pat. No. US 6649607

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-292026P	20010518 (60) <--
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DRINKER BIDDLE & REATH, ATTN: INTELLECTUAL PROPERTY GROUP, ONE LOGAN SQUARE, 18TH AND CHERRY STREETS, PHILADELPHIA, PA, 19103-6996, US	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	708	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions comprising S-tofisopam substantially free of R-tofisopam, and methods for treating or preventing convulsions and/or seizures comprising administration of the composition to subjects in need of treatment therefore. Also provided are compositions and methods for treating or preventing convulsions and/or seizures comprising administering S-tofisopam substantially free of R-tofisopam with another anti-convulsant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 82059-50-5P, R-Tofisopam
(S-tofisopam for treating or preventing convulsions or seizures)

RN 82059-50-5 USPATFULL

CN 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 82059-51-6P, S-Tofisopam
(S-tofisopam for treating or preventing convulsions or seizures)

RN 82059-51-6 USPATFULL

CN 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 22345-47-7P, Tofisopam
(S-tofisopam for treating or preventing convulsions or seizures, and use with other anticonvulsants)
RN 22345-47-7 USPATFULL
CN 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl- (CA INDEX NAME)



IT 476625-20-4P 476625-22-6P
(S-tofisopam for treating or preventing convulsions or seizures, and use with other anticonvulsants)
RN 476625-20-4 USPATFULL
CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine (9CI) (CA INDEX NAME)

CM 1

CRN 82059-50-5
CMF C22 H26 N2 O4
CDES 1:R

Absolute stereochemistry.



CM 2

CRN 2743-38-6
CMF C18 H14 O8

Absolute stereochemistry. Rotation (-).



RN 476625-22-6 USPATFULL
CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2S,3S)-, compd. with (5S)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine (9CI) (CA INDEX NAME)

CM 1

CRN 82059-51-6
CMF C22 H26 N2 O4
CDES 1:S

Absolute stereochemistry.



CM 2

CRN 17026-42-5
CMF C18 H14 O8

Absolute stereochemistry. Rotation (+).



L20 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER:	2005:87864 USPATFULL Full-text
TITLE:	Compositions and methods for treating or preventing convulsions or seizures
INVENTOR(S):	Leventer, Steven M., Langhorne, PA, UNITED STATES Kucharik, Robert F., Glenmoore, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005075329	A1	20050407
	US 7078398	B2	20060718
APPLICATION INFO.:	US 2003-625754	A1	20030723 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-8516, filed on 8 Nov 2001, GRANTED, Pat. No. US 6649607

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-292026P	20010518 (60) <--

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Vela Pharmaceuticals, 3528 Old Baptist Rd., Collegeville, PA, 19426
NUMBER OF CLAIMS:	27
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	6 Drawing Page(s)
LINE COUNT:	788

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions comprising S-tofisopam substantially free of R-tofisopam, and methods for treating or preventing convulsions and/or seizures comprising administration of the composition to subjects in need of treatment therefor. Also provided are compositions and methods for treating or preventing convulsions and/or seizures comprising administering S-tofisopam substantially free of R-tofisopam with another anti-convulsant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 82059-50-5P, R-Tofisopam
(S-tofisopam for treating or preventing convulsions or seizures)

RN 82059-50-5 USPATFULL
CN 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 82059-51-6P, S-Tofisopam
(S-tofisopam for treating or preventing convulsions or seizures)
RN 82059-51-6 USPATFULL
CN 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 22345-47-7P, Tofisopam
(S-tofisopam for treating or preventing convulsions or seizures, and use with other anticonvulsants)
RN 22345-47-7 USPATFULL
CN 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl- (CA INDEX NAME)



IT 476625-20-4P 476625-22-6P
(S-tofisopam for treating or preventing convulsions or seizures, and use with other anticonvulsants)
RN 476625-20-4 USPATFULL
CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine (9CI) (CA INDEX NAME)

CM 1

CRN 82059-50-5
CMF C22 H26 N2 O4
CDES 1:R

Absolute stereochemistry.



CM 2

CRN 2743-38-6
CMF C18 H14 O8

Absolute stereochemistry. Rotation (-).



RN 476625-22-6 USPATFULL
CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2S,3S)-, compd. with (5S)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine (9CI) (CA INDEX NAME)

CM 1

CRN 82059-51-6
CMF C22 H26 N2 O4
CDES 1:S

Absolute stereochemistry.



CM 2

CRN 17026-42-5
CMF C18 H14 O8

Absolute stereochemistry. Rotation (+).



L20 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2003:79121 USPATFULL Full-text
TITLE: Compositions and methods for treating or preventing convulsions or seizures
INVENTOR(S): Leventer, Steven M., Langhorne, PA, UNITED STATES
Kucharik, Robert, Glenmoore, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055048	A1	20030320
	US 6649607	B2	20031118
APPLICATION INFO.:	US 2001-8516	A1	20011108 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-292026P	20010518 (60) <--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 785
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions comprising S-tofisopam substantially free of R-tofisopam, and methods for treating or preventing convulsions and/or seizures comprising administration of the composition to subjects in need of treatment therefor. Also provided are compositions and methods for treating or preventing convulsions and/or seizures comprising administering S-tofisopam substantially free of R-tofisopam with another anti-convulsant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 82059-50-5P, R-Tofisopam
(S-tofisopam for treating or preventing convulsions or seizures)
RN 82059-50-5 USPATFULL
CN 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 82059-51-6P, S-Tofisopam
(S-tofisopam for treating or preventing convulsions or seizures)
RN 82059-51-6 USPATFULL
CN 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-

methyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 22345-47-7P, Tofisopam
(S-tofisopam for treating or preventing convulsions or seizures, and use with other anticonvulsants)
RN 22345-47-7 USPATFULL
CN 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl- (CA INDEX NAME)



IT 476625-20-4P 476625-22-6P
(S-tofisopam for treating or preventing convulsions or seizures, and use with other anticonvulsants)
RN 476625-20-4 USPATFULL
CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine (9CI) (CA INDEX NAME)

CM 1

CRN 82059-50-5
CMF C22 H26 N2 O4
CDES 1:R

Absolute stereochemistry.



CM 2

CRN 2743-38-6
CMF C18 H14 O8

Absolute stereochemistry. Rotation (-).



RN 476625-22-6 USPATFULL
CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2S,3S)-, compd. with (5S)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine (9CI) (CA INDEX NAME)

CM 1

CRN 82059-51-6
CMF C22 H26 N2 O4
CDES 1:S

Absolute stereochemistry.



CM 2

CRN 17026-42-5
CMF C18 H14 O8

Absolute stereochemistry. Rotation (+).